Profile of Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections in Bhutan.
Bhim Bahadur RaiDeepa RaiMichael G MorleyPublished in: Clinical ophthalmology (Auckland, N.Z.) (2023)
Limited human resources for managing VR diseases in Bhutan are compounded by economic and geographic challenges. With increasing VR diseases such as nAMD and myopia and complications of systemic diseases such as DR, DMO and RVO, there is a need to improve VR services. Currently, anti-VEGF is procured only for a pooled patients requiring IVI, and patients are lost due to longer waiting periods. Bhutan needs to assess if females are reporting less or are not receiving treatment due to cultural barriers and social stigma.
Keyphrases
- vascular endothelial growth factor
- mental health
- endothelial cells
- newly diagnosed
- healthcare
- ejection fraction
- primary care
- clinical trial
- randomized controlled trial
- hepatitis c virus
- mental illness
- emergency department
- study protocol
- ultrasound guided
- hiv infected
- diabetic retinopathy
- phase iii
- hiv aids
- platelet rich plasma
- affordable care act